Skip to main content

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2022

HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2022, on Tuesday, March 15, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 692343. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 44896, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a data-driven research organization, with headquarters in the United States, that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration.

For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/692638/Champions-Oncology-to-Announce-Third-Quarter-Financial-Results-on-Tuesday-March-15-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.90
+6.42 (2.97%)
AAPL  263.44
+1.19 (0.46%)
AMD  239.09
-1.47 (-0.61%)
BAC  51.73
-0.31 (-0.61%)
GOOG  252.18
-4.84 (-1.88%)
META  732.47
+0.30 (0.04%)
MSFT  517.14
+0.35 (0.07%)
NVDA  181.29
-1.34 (-0.74%)
ORCL  275.36
-1.82 (-0.66%)
TSLA  445.80
-1.63 (-0.36%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.